

S100A8/9 modulates perturbation and glycolysis of macrophages in allergic asthma mice

Xiaoyi Ji ^{1,2}, Chunhua Nie ², Yuan Yao ², Yu Ma ¹, Huafei Huang ², Chuangli Hao ^{Corresp. 1}

¹ Department of Respiratory Medicine, Children's Hospital of Soochow University, Suzhou, China

² Jiaxing Maternal and Child Health Hospital, Jiaxing, China

Corresponding Author: Chuangli Hao

Email address: hcl_md@sina.com

Background. Allergic asthma is the most prevalent asthma phenotype and is associated with the disorders of immune cells and glycolysis. Macrophages are the most common type of immune cells in the lungs. Calprotectin (S100A8 and S100A9) are two pro-inflammatory molecules that target the Toll-like receptor 4 (TLR4) and are substantially increased in the serum of patients with severe asthma. This study aimed to determine the effects of S100A8/A9 on macrophage polarization and glycolysis associated with allergic asthma.

Methods. To better understand the roles of S100A8 and S100A9 in the pathogenesis of allergic asthma, we used ovalbumin (OVA)-induced MH-S cells, and OVA-sensitized and challenged mouse models (wild-type male BALB/c mice). Enzyme-linked immunosorbent assay, quantitative real-time polymerase chain reaction, flow cytometry, hematoxylin-eosin staining, and western blotting were performed. The glycolysis inhibitor 3-bromopyruvate (3-BP) was used to observe changes in glycolysis in mice.

Results. We found knockdown of S100A8 or S100A9 in OVA-induced MH-S cells inhibited inflammatory cytokines, macrophage polarization biomarker expression, and pyroptosis cell proportion, but increased anti-inflammatory cytokine interleukin (IL)-10 mRNA; also, glycolysis was inhibited, as evidenced by decreased lactate and key enzyme expression; especially, knockdown of S100A8 or S100A9 inhibited the activity of TLR4/ myeloid differentiation primary response gene 88 (MyD88)/ Nuclear factor kappa-B (NF- κ B) signaling pathway. Intervention with lipopolysaccharides (LPS) abolished the beneficial effects of S100A8 and S100A9 knockdown. The observation of OVA-sensitized and challenged mice showed that S100A8 or S100A9 knockdown promoted respiratory function, improved lung injury, and inhibited inflammation; knockdown of S100A8 or S100A9 also suppressed macrophage polarization, glycolysis levels, and activation of the TLR4/MyD88/NF- κ B signaling pathway in the lung. Conversely, S100A9 overexpression exacerbated lung injury and inflammation, promoting macrophage polarization and glycolysis, which were antagonized by the glycolysis inhibitor 3-BP.

Conclusion. S100A8 and S100A9 play critical roles in allergic asthma pathogenesis by promoting macrophage perturbation and glycolysis through the TLR4/MyD88/NF- κ B signaling pathway. Inhibition of S100A8 and S100A9 may be a potential therapeutic strategy for allergic asthma.

1 **S100A8/9 modulates perturbation and glycolysis of** 2 **macrophages in allergic asthma mice**

3

4

5 Xiaoyi Ji^{1,2}, Chunhua Nie², Yuan Yao², Yu Ma¹, Huafei Huang², Chuangli Hao¹

6

7 ¹ Department of Respiratory Medicine, Children's Hospital of Soochow University, Suzhou,
8 China9 ² Jiaxing Maternal and Child Health Hospital, Jiaxing, China

10

11 Corresponding Author:

12 Chuangli Hao¹

13 Jingde Road No. 303, Suzhou, Jiangsu 215003, China

14 Email address: hcl_md@sina.com

15

16 **Abstract**17 **Background.** Allergic asthma is the most prevalent asthma phenotype and is associated with the
18 disorders of immune cells and glycolysis. Macrophages are the most common type of immune
19 cells in the lungs. Calprotectin (S100A8 and S100A9) are two pro-inflammatory molecules that
20 target the Toll-like receptor 4 (TLR4) and are substantially increased in the serum of patients
21 with severe asthma. This study aimed to determine the effects of S100A8/A9 on macrophage
22 polarization and glycolysis associated with allergic asthma.23 **Methods.** To better understand the roles of S100A8 and S100A9 in the pathogenesis of allergic
24 asthma, we used ovalbumin (OVA)-induced MH-S cells, and OVA-sensitized and challenged
25 mouse models (wild-type male BALB/c mice). Enzyme-linked immunosorbent assay,
26 quantitative real-time polymerase chain reaction, flow cytometry, hematoxylin-eosin staining,
27 and western blotting were performed. The glycolysis inhibitor 3-bromopyruvate (3-BP) was used
28 to observe changes in glycolysis in mice.29 **Results.** We found knockdown of S100A8 or S100A9 in OVA-induced MH-S cells inhibited
30 inflammatory cytokines, macrophage polarization biomarker expression, and pyroptosis cell
31 proportion, but increased anti-inflammatory cytokine interleukin (IL)-10 mRNA; also, glycolysis
32 was inhibited, as evidenced by decreased lactate and key enzyme expression; especially,
33 knockdown of S100A8 or S100A9 inhibited the activity of TLR4/ myeloid differentiation
34 primary response gene 88 (MyD88)/ Nuclear factor kappa-B (NF- κ B) signaling pathway.
35 Intervention with lipopolysaccharides (LPS) abolished the beneficial effects of S100A8 and
36 S100A9 knockdown. The observation of OVA-sensitized and challenged mice showed that
37 S100A8 or S100A9 knockdown promoted respiratory function, improved lung injury, and
38 inhibited inflammation; knockdown of S100A8 or S100A9 also suppressed macrophage
39 polarization, glycolysis levels, and activation of the TLR4/MyD88/NF- κ B signaling pathway in

40 the lung. Conversely, S100A9 overexpression exacerbated lung injury and inflammation,
41 promoting macrophage polarization and glycolysis, which were antagonized by the glycolysis
42 inhibitor 3-BP.

43 **Conclusion.** S100A8 and S100A9 play critical roles in allergic asthma pathogenesis by
44 promoting macrophage perturbation and glycolysis through the TLR4/MyD88/NF- κ B signaling
45 pathway. Inhibition of S100A8 and S100A9 may be a potential therapeutic strategy for allergic
46 asthma.

47

48 **Introduction**

49 Asthma is a chronic inflammatory disease of the airways, clinically characterized by recurrent
50 episodes of wheezing, chest tightness, or coughing, and its triggers include “extrinsic” (allergic
51 asthma) and “intrinsic” (non- allergic asthma) (Padem and Saltoun 2019; Ioachimescu and Desai
52 2019). The prevalence of asthma ranges from 3.44% to 8.33% across all continents. Asthma
53 sufferers have a reduced quality of life, and their families often account for a heavy healthcare
54 cost burden (Rabe et al. 2023). Allergic asthma is the most common asthma phenotype,
55 occurring on average at a younger age than endogenous asthma (Schatz and Rosenwasser 2014)
56 and is described as a chronic lung disease characterized by reversible airway obstruction, leading
57 to airflow limitation and the manifestation of physiological symptoms (Hough et al. 2020).

58 Macrophages, which are the most abundant immune cells in the lungs (approximately 70% of all
59 immune cells), play an important role in allergic asthma caused by exogenous allergens (Lee et
60 al. 2015; Holt 1986). They are essential innate immune cells mainly classified as classical
61 polarization (M1) or alternative polarization (M2). M1 macrophages are usually considered to
62 have pro-inflammatory phenotypes with potent phagocytic and cytotoxic capacities, which are
63 mainly defined by the expression of major compatibility complex II (MHCII), cluster of
64 differentiation (CD) 14, CD80/CD86, CD38, and inducible nitric oxide synthase (iNOS)
65 (Saradna et al. 2018). In contrast to M1 macrophages, M2 macrophages are considered to play a
66 role in the abrogation of inflammatory and tissue repair pathways by expressing the cell surface
67 biomarkers CD36, CD206, and CD163 (Müller et al. 2007; Dewhurst et al. 2017). However, a
68 drastic change in the proportion of polarized macrophages was found in humans and mice with
69 allergic asthma or lung inflammation; MHCII-hi macrophages (M1) and CD206⁺ macrophages
70 (M2) both increased, but interleukin (IL)-10⁺ macrophages decreased (Draijer et al. 2022)
71 suggesting a relationship between asthma and macrophages. CD86 and CD206 are key markers
72 that distinguish between M1 and M2 macrophages, and their expression is markedly increased in
73 allergic asthma (Morsi et al. 2023). Arginase 1 (Arg1), found in the inflammatory zone 1 (Fizz-
74 1) is also a biomarker of M2 macrophages (Xu et al. 2020). In addition, activation of M2
75 macrophages promotes airway inflammation in asthma (Zhong et al. 2023). The homeostasis of
76 macrophage perturbations is a key mechanism of airway inflammation in asthma; however, the
77 exact mechanism remains poorly understood.

78 Over the past three years, immune metabolism studies in allergies have found that asthma is
79 associated with increased aerobic glycolysis (Goretzki et al. 2023). A study of serum lactate acid

80 levels in clinically stable patients with allergic asthma, healthy controls, and patients with
81 chronic obstructive pulmonary disease (COPD) found that its content was substantially higher in
82 patients than in healthy controls, which was also significantly higher than that in controls of
83 patients with COPD (Ostroukhova et al. 2012) suggesting an increase in glycolysis. Metabolism
84 is critical for cellular activity as it provides energy and ATP, including the regulation of
85 macrophages under homeostatic conditions and stress (El Kasmi and Stenmark 2015). It has been
86 found that under homeostatic conditions, the metabolic characteristics of macrophages are
87 consistent with mitochondrial oxidative phosphorylation (OXPHOS) using glucose and oxygen
88 (Kelly and O'Neill 2015). *In vitro* studies have found that lipopolysaccharides (LPS), a Toll-like
89 receptor 4 (TLR4) agonist, induced inflammatory macrophages decreased OXPHOS levels,
90 along with an increase in the metabolism of glucose to lactate acid (Palsson-McDermott et al.
91 2015). In particular, there is evidence indicating that alveolar macrophages show a diminished
92 response to IL-4 when recovering from *in vitro* incubation for 48 h. Additionally, the competitive
93 glucose inhibitor 2-Deoxy-d-glucose (2-DG) significantly hinders the IL-4 induced up-regulation
94 of Retnla, Arg1, and Chil2 (M2 macrophage biomarkers) in alveolar macrophages during *in vitro*
95 incubation. This suggests that the lung environment plays a role in regulating metabolism,
96 thereby influencing the polarization of alveolar macrophages (Svedberg et al. 2019).

97 S100A8 and S100A9 are two pro-inflammatory molecules belonging to the S100 family of
98 calcium-binding proteins that normally form a heterodimeric complex (S100A8/A9, also known
99 as calreticulin A and B) after being released from myeloid cells (Vogl et al. 2006). Their levels
100 were significantly increased in the serum of patients with severe asthma compared to healthy
101 controls (Decaesteker et al. 2022). Lee et al. found that in allergic asthmatic mice with type 2
102 airway inflammation, serum S100A8/A9 levels were correlated with lung function and airway
103 hyperresponsiveness, implying that S100A8/A9 serves as a biomarker for asthma (Lee et al.
104 2020). Another study found that macrophages in the peripheral blood of patients with severe
105 asthma expressed more S100A9 than those of patients with non-severe asthma (Quoc et al.
106 2021). A recent study reported that hexokinase (HK) 1 and glyceraldehyde-3-phosphate
107 dehydrogenase (GAPDH) activities in macrophages from low-grade inflammation in humans and
108 mice were reduced. HK1 interacting with S100A8/A9 can blockade glycolysis below GAPDH
109 by nitrosylating GAPDH via nitric oxide synthase 2 (iNOS) (De Jesus et al. 2022). HK1 is an
110 HK isoform and is one of the key enzymes involved in glucose phosphorylation (the first step in
111 the glucose metabolism pathway), which includes HK1, HK2, and HK3 (Yang et al. 2022). It has
112 been suggested that S100A8/A9 can regulate macrophage glycolysis in patients with allergic
113 asthma. A study reported that S100A8/A9 complex played a key role in macrophage polarization
114 to trigger inflammation in sepsis, as the endogenous ligand for TLR4, induced intracellular
115 translocation of myeloid differentiation primary response gene 88 (MyD88) as well as Nuclear
116 factor kappa-B (NF- κ B) activation to promote Tumor Necrosis Factor (TNF)- α expression (Vogl
117 et al. 2007). Li et al. found that regulation of the TLR4/MyD88/NF- κ B signaling pathway
118 inhibited macrophage inflammation (Li et al. 2021b). LPS activates TLR4 and triggers MyD88
119 and TIR domain-containing adaptor, inducing interferon- β (TRIF) signaling cascades to induce

120 inflammation (Ciesielska et al. 2021). The metabolic enzyme ATP citrate lyase (ACLY) is a
121 producer of citrate-derived acetyl-coenzyme A (CoA), which plays a critical role in supporting
122 the pro-inflammatory response (Santarsiero et al. 2021). TLR4 activates ACLY to induce the
123 inflammatory response (Lauterbach et al. 2019). S100A8 and S100A9, the pro-inflammatory
124 proteins targeting the TLR4, deserve further exploration for their roles in macrophage
125 polarization and glycolytic metabolism.

126 Moreover, macrophage polarization is related to cellular metabolism and pyroptosis, and
127 inhibition of glycolysis suppresses pyroptosis (Zasłona et al. 2020; Aki et al. 2022). S100A8 and
128 S100A9 may be involved in the regulation of macrophage polarization, glycolytic metabolism,
129 and pyroptosis in allergic asthma. Therefore, we established ovalbumin (OVA)-induced alveolar
130 macrophage models to observe the effects of S100A8 and S100A9 on macrophage polarization.
131 In addition, we established OVA-sensitized and -challenged mouse models to verify the
132 protective effects of sh-S100A8 and sh-S100A9. This study aims to provide a scientific basis for
133 exploring the effects of macrophage polarization and glycolytic metabolism on allergic asthma
134 and provides new ideas for improving allergic asthma.

135

136 **Materials & Methods**

137 **Cell culture and modeling**

138 Mouse alveolar macrophages MH-S (iCell-m078, iCell Bioscience, China) were cultured in
139 complete medium containing DMEM, 10% fetal bovine serum (13011-8611, Every Green,
140 China), 0.05 mM β -mercaptoethanol (M6250, Sigma-Aldrich, USA) and 1%
141 penicillin/streptomycin (C0222, Beyotime, China). In addition, Lipofectamine 2000 (11668019,
142 Invitrogen, USA) with sh-S100A8 or sh-S100A9 was incubated with cells (2×10^5 cells/well) in
143 6-well plates for 48 h. Furthermore, macrophage polarization was induced for 8 h with OVA
144 (Wang et al. 2021). Lipopolysaccharide (LPS) (100 ng/mL, HY-D1056, MedChemExpress,
145 USA) as a TLR4 agonist was incubated with MH-S cells for 8 h (Alhouayek et al. 2013) with
146 PBS as a control. The cells were divided into Control, OVA, OVA + sh-S100A8, OVA + sh-
147 S100A9, OVA + sh-S100A8 + LPS, and OVA + sh-S100A9 + LPS groups. Cell experiments of
148 cells were repeated independently at least thrice.

149 **Animals with allergic asthma and grouping**

150 Wild-type male BALB/c mice (approximately 19 g), aged 6–8 weeks, from Lingchang Biotech
151 Co., Ltd, (Shanghai, China). The mice were kept in ventilated cages in a pathogen-free animal
152 facility and provided free access to food and water. All animal protocols were performed by
153 professionals blinded to the group assignment in compliance with the Guidelines for the Humane
154 Treatment of Laboratory Animals and were approved by the Animal Experimentation Ethics
155 Committee of Zhejiang Eyong Pharmaceutical Research and Development Center (approval
156 number: ZJEY-20221205-02).

157 We injected mice with physiological saline, lentivirus-sh-S100A8/A9, or lentivirus-S100A9 ($1 \times$
158 10^9 viral particles per mouse) through the tail vein a week before OVA sensitization. The mice
159 were sensitized and challenged with OVA (A5503, Sigma, USA) as previously described (Li et

160 al. 2021a). Briefly, we injected mice intraperitoneally 10 µg of OVA in 1 mg aluminum
161 hydroxide (239186, Sigma, USA) with 20 g Freund's adjuvant (77140, Thermo, USA) on days 0,
162 7 and 14. We subsequently challenged the mice with an OVA aerosol using an ultrasonic
163 nebulizer (Pari Proneb nebulizer, Midlothian, WA, USA) with a 1% (wt/vol) OVA solution in
164 saline for 20 min on days 15-21, once a day. Additionally, we intraperitoneally injected 3-
165 bromopyruvate (3-BP, 5 mg/kg/day) into the mice once every 2 days (Fang et al. 2019) to
166 observe glycolysis.

167 Randomized allocation of animals using the random number table method. We divided 24 mice
168 into four groups to observe the effects of S100A8 and S100A9 knockdown on allergic asthma (6
169 mice per group): negative control (NC), OVA, OVA + sh-S100A8, and OVA + sh-S100A9
170 groups. Additionally, 24 mice were divided into four groups to observe glycolysis (six mice per
171 group): OVA, OVA + 3-BP, OVA + OE-S100A9, and OVA + S100A9 + 3-BP. In animal
172 experiments, if the animals suffered infections and showed a sudden weight loss of more than
173 20% in one week, they were euthanized by CO₂ asphyxiation. In this study, the body weight,
174 nutrition, and activity levels of the animals were normal. Therefore, none of these animals were
175 excluded from the study. On day 22, a small-animal ventilator (flexiVent, SCIREQ, Canada) was
176 used to assess respiratory function in mice administered pentobarbital sodium for anesthesia.
177 After mice were anesthetized with isoflurane on day 23, orbital blood was sampled to detect
178 OVA-specific IgE and lactic acid. Following this, the mice were euthanized with carbon dioxide.
179 Subsequently, bronchoalveolar lavage fluid (BALF) was collected for inflammatory cell counts,
180 flow cytometry, and detection of inflammatory factors. After lavage, the lungs were isolated to
181 fix for immunohistochemistry and histological observation or frozen at -80°C for detection of
182 gene and protein levels.

183 **Detection of mRNAs by quantitative real-time PCR**

184 Through lysis and centrifugation, total RNAs of fresh cells or tissues (frozen at -80°C) were
185 extracted using a total RNA small extraction kit (B618583-0100, Sangon, China). Total RNA
186 was treated with RNase-free DNaseI. RNase-free water (20 µL; Am9932, Thermo Fisher
187 Scientific, Waltham, MA, USA) was used to dissolve the total RNA, and an ultra-micro
188 spectrophotometer (Nanodrop One, Thermo Fisher Scientific) was used to determine its
189 concentration and purity. Samples with ratios of 260/280 nm values between 1.9 and 2.1 and
190 260/230 nm values greater than 2.0, were used for subsequent experiments. HiFiScript cDNA
191 Synthesis Kit (CW2569, CWBIO, China) and SYBR Green qPCR Kit (11201ES08, YEASEN,
192 China) were used for reverse transcription and stored at -20°C pending analysis. Subsequently,
193 quantitative real-time PCR (qRT-PCR) was performed using a LightCycler96 qRT-PCR
194 instrument (Roche, Switzerland). The cycling conditions were determined according to the
195 manufacturer's instructions. β-actin was used as an endogenous control. All data were processed
196 by relative quantitative method (2^{-ΔΔCt}). The primer sequences are listed in Table 1. Genomic
197 DNA contamination was not detected in the qRT-PCR products.

198 **Detection of inflammatory factors, lactic acid content, and glycolysis**

199 Cell supernatant was used to detect the concentration of IL-1 β (MM-0040M2, MEIMIAN,
200 China), IL-6 (MM-0163M2, MEIMIAN), and TNF- α (MM-0132M2, MEIMIAN) using ELISA.
201 In addition, after testing respiratory function, blood was collected via orbital blood collection,
202 isoflurane-anesthetized mice were euthanized with CO₂, the lungs were lavaged twice with 1 mL
203 of cold PBS, and BALF was collected. Serum OVA-specific IgE and lactic acid levels were
204 detected using ELISA (MM-45386M2, MEIMIAN, China) and a lactic acid content detection kit
205 (BC2230, Solarbio, China). Supernatant of BALF was counted to detect the concentration of IL-
206 4 (MM-01065M2, MEIMIAN), IL-13 (MM-0173M2, MEIMIAN), TGF- β 1 (MM-0135M2,
207 MEIMIAN), TNF- α , and INF- γ (MM-0182M2, MEIMIAN). The extracellular acidification rate
208 (EACR) kit (BB48311, BestBio, China), phosphofructokinase (PFK) kit (BC0530, Solarbio,
209 China), and hexokinase (HK) kit (BC0745, Solarbio) were used to observe glycolysis in cells.
210 Assays were performed using a multifunctional microplate reader (CMaxPlus, San Francisco,
211 MD, USA).

212 **Inflammatory cell count**

213 BALF cells were centrifuged (Cytospin 500, Sandton, UK) at 3000 rpm for 5 min at 22°C using
214 cell centrifugation. Then, the cells on slides were stained with the Wright-Giemsa Staining kit
215 (D010-1-2, Nanjing Jiancheng, China), air-dried, and fixed with Permount Mounting Medium
216 (MM1411, MKBio, China). The slides were observed under a microscope, and at least 300 cells
217 were counted for each preparation.

218 **Polarization and pyroptosis detection by flow cytometry**

219 To confirm MH-S cells and lung macrophage polarization and pyroptosis were analyzed by flow
220 cytometry. After processing the cells according to the grouping, MH-S cells were prepared into 2
221 $\times 10^7$ cells/mL PBS suspensions. Subsequently, the FITC anti-F4/80 (ab60343, Abcam,
222 Cambridge, UK), APC anti-CD86 (ab218757, Abcam), and PE/Cy7 anti-mannose receptor [15-
223 2] (CD206) (ab270682, Abcam) antibodies were incubated with MH-S cells at 4 °C for 15 min.
224 Additionally, the BALF was centrifuged at 1000 rpm for 5 min to collect the cells. Cells from
225 BALF resuspended by PBS to 2 $\times 10^7$ cells/mL and were incubated at 4 °C for 15 min with
226 antibodies including Alexa Fluor® 700 anti- CD45 (157210, Biolegend, San Diego, CA, USA),
227 FITC anti-F4/80, APC anti-CD86, PE/Cy7 anti-mannose receptor [15-2] (CD206), and PE anti-
228 CD11b (ab25175, Abcam). The gating strategy of BALF is described in Supplementary Fig. 1.
229 For pyroptosis, the FLICA 660 Caspase-1 (9122, ImmunoChemistry, Bloomington, MN, USA)
230 and PI staining (556547, BD, Franklin Lakes, NJ, USA) were used to incubate the cells at 37 °C
231 for 15 min. The percentage of cells that were double-positive for caspase-1 and PI was used to
232 indicate pyroptosis. All cells were screened through a 200-mesh sieve and flow cytometry
233 (NovoCyte, Agilent, Santa Clara, CA, USA) was used to detect the proportion of cells.

234 **Hematoxylin and eosin staining and immunohistochemistry**

235 After euthanasia, the lungs were isolated from the mice, fixed with 4% paraformaldehyde for 24
236 h, and embedded in paraffin blocks. Subsequently, lung histopathology was performed using
237 hematoxylin and eosin (HE) staining. Lung paraffin blocks were sliced into 4 μ m sections,
238 dewaxed, and hydrated. Finally, the sections were stained using an HE kit (C0105S, Beyotime,

239 Shanghai, China) to observe morphology and cell morphology under a Nikon Eclipse Ci-L
240 microscope (Tokyo, Japan).

241 **Western blot**

242 Cell or tissue proteins were extracted using RIPA solution (P0013C, Beyotime) containing
243 protease inhibitors (CW2200S, CWBIO, Beijing, China). After extraction and denaturation of
244 total proteins, 10% gel electrophoresis was used to separate the proteins, and activated PVDF
245 membranes were used for transfer. Subsequently, the blocked-membranes with 5% skim milk
246 powder were incubated with primary antibodies such like anti-TLR4 (1:1000, 14358S, CST,
247 Boston, MA, USA), anti-MyD88 (1:1000, ab219413, Abcam), anti- TIR domain containing
248 adaptor molecule 1 (TRIF) (1:3000, ab13810, Abcam), anti-NF- κ B (1:3000, 8242T, CST), anti-
249 I κ B α (1:3000, 4814T, CST), Anti-ATP citrate lyase antibody (ACLY) (1:10000, ab40793,
250 Abcam), phospho- ACLY (1:1000, 4331T, CST), and anti- β -actin (1:20000, 81115-1-RR,
251 Proteintech, Chicago, IL, USA) followed by corresponding secondary antibodies (1:6000,
252 7074/7076, CST) at 25 °C for 2 h. The membrane was incubated with ECL reagents (610020-
253 9Q, Qing Xiang, Shanghai, China) and visualized by ImageJ software.

254 **Statistical analysis**

255 The statistical software SPSS 19.0 (IBM, Armonk, NY, USA) was used to analyze the data, and
256 the continuous variables were presented as mean \pm standard deviation. Data from multiple *in*
257 *vivo* experiments were analyzed using one-way analysis of variance (ANOVA) with a post-hoc
258 Tukey test. In cases where measurement data were not normally distributed, the Kruskal-Wallis
259 H test was used. Any *p*-value that resulted in lower than 0.05 was deemed statistically
260 significant.

261

262 **Results**

263 **1. S100A8/9 knockdown inhibited polarization of ovalbumin-induced MH-S model**

264 We examined the effects of S100A8 and S100A9 knockdowns on MH-S cell polarization and
265 inflammation. As shown in supplementary Fig. 2, the S100A9 or S100A8 knockdown cell
266 models were successfully established. The concentrations of the inflammatory factors, IL-1 β , IL-
267 6, and TNF- α were significantly increased in the OVA group (*p*< 0.01), while the knockdown of
268 S100A8 or S100A9 decreased their concentrations (*p*< 0.01) (Fig. 1A-C). We detected
269 biomarkers mRNA of M1 macrophage (IL-6, IL-1 β , and iNOS) and M2 macrophage (IL-10,
270 Arg1, and Fizz1) and found that they were increased in the OVA group, except for IL-10
271 (*p*<0.01), while knockdown of S100A8 or S100A9 decreased IL-6, IL-1 β , iNOS, Arg1 and Fizz1
272 mRNA and increased IL-10 mRNA (*p*<0.01) (Fig. 1D-I). Furthermore, we detected the
273 proportion of M1 (CD86+) and M2 (CD206+) cells using flow cytometry (Fig. 1J, K). In the
274 OVA group, the proportion of M1 (CD86+) and M2 (CD206+) cells was increased, whereas
275 S100A8 or S100A9 knockdown inhibited this increase (*p*< 0.01) (Fig. 1J, K). Additionally, LPS
276 intervention antagonized the effects of S100A8 or S100A9 knockdown on OVA-induced MH-S
277 cell injury models (*p*< 0.05) (Fig. 1A-K). These results suggest that the knockdown of S100A8

278 or S100A9 has an inhibitory effect on OVA-induced macrophage polarization, whereas LPS is a
279 TLR4 agonist that can partially antagonize this inhibitory effect.

280

281 **2. S100A8/9 knockdown inhibited pyroptosis and glycolysis of ovalbumin-induced MH-S 282 model**

283 We measured pyroptosis and found that the knockdown of S100A8 or S100A9 significantly
284 reduced MH-S cell pyroptosis ($p < 0.05$), while LPS antagonized it ($p < 0.01$) (Fig. 1N, O). We
285 also measured the EACR to observe glycolysis in MH-S cells. OVA intervention significantly
286 decreased EACR at 1-63 min ($p < 0.01$) (Table 2). S100A8 knockdown significantly decreased
287 ECAR of MH-S cells with OVA intervention, except at 1 and 36 min ($p < 0.05$) (Table 2).
288 S100A9 knockdown significantly decreased ECAR of MH-S cells with OVA intervention at 9-
289 63 min ($p < 0.05$) (Table 2). LPS intervention significantly counteracted the inhibitory effect of
290 S100A8 knockdown ($p < 0.05$) and in OVA-inverted MH-S cells with S100A9 knockdown, LPS
291 intervention significantly increased the ECAR at 9, 18, 27, 45, 54, and 63 min ($p < 0.05$) (Table
292 2). Furthermore, the concentrations of lactic acid, FPK, and HK were increased in MH-S cells
293 treated with OVA intervention ($p < 0.01$) (Fig. 2A-C). We also measured the mRNA levels of
294 glycolysis-related genes. In OVA-induced MH-S cells, GAPDH, HK2, and LDHA mRNA levels
295 significantly increased, whereas PDH mRNA levels decreased ($p < 0.01$) (Fig. 2D-F). S100A8 or
296 S100A9 knockdown inhibited GAPDH, HK2, and LDHA mRNA expression in OVA-induced
297 MH-S cell injury models and increased PDH mRNA levels ($p < 0.01$); however, LPS intervention
298 antagonized these effects ($p < 0.05$) (Fig. 2D-G). The activation of the TLR4/MyD88/TRIF/NF-
299 κ B signaling pathway promotes glycolysis (Li et al. 2021b). Therefore, we detected the
300 TLR4/MyD88/TRIF/NF- κ B signaling pathway by Western blot. The levels of TLR4, MyD88,
301 TRIF, NF- κ B, and p-ACLY/ACLY in MH-S cells were increased and S100A8 or S100A9
302 knockdown decreased them ($p < 0.01$), while LPS intervention partially antagonized the
303 inhibition of S100A8 or S100A9 knockdown on TLR4/MyD88/TRIF/NF- κ B signaling pathway
304 ($p < 0.05$) (Fig. 2H-K, M, N). Furthermore, I κ B α expression levels had the opposite trend to
305 these proteins ($p < 0.05$) (Fig. 2L, N). We found that S100A8 or S100A9 knockdown inhibited
306 macrophage pyroptosis and glycolysis through the TLR4/MyD88/TRIF/NF- κ B signaling
307 pathway.

308

309 **3. S100A8/9 knockdown improved respiratory function, lung tissue injury, and 310 inflammation of BALF in ovalbumin-sensitized and challenged mice**

311 We established a mouse model of allergic asthma using OVA to observe the protective effects of
312 S100A8 and S100A 9 knockdown in the lungs post-OVA-challenged. As shown in
313 supplementary Fig. 3, we successfully established OVA-sensitized and -challenged mice with
314 S100A8 or S100A9 knockdown. To verify the role of S100A8 and S100A9 in allergic asthma
315 mice, we assessed respiratory function, observed pathological damage to lung tissue, and
316 measured the levels of inflammatory cells and cytokines in BALF. The respiratory function

317 indicators tidal volume (TV), vital capacity (VC), expiratory volume (EV), minute ventilation
318 volume (MV), forced expiratory volume in 0.1 seconds (FEV0.1), end inspiratory pause (EIP),
319 peak expiratory flow (PEF), mid expiratory flow (EF50), and dynamic lung compliance (Cdyn)
320 in OVA mice were markedly decreased while S100A8 and S100A9 knockdown reversed them
321 ($p < 0.01$) (Fig. 3A-I). Mice with OVA-sensitized and -challenged had increased serum OVA-
322 specific IgE levels ($p < 0.01$) (Fig. 3J), whereas S100A8 or S100A9 knockdown markedly
323 decreased IgE levels compared to those in the OVA group ($p < 0.01$) (Fig. 3J). Histological
324 analysis indicated an increase in peribronchial inflammatory infiltrates in the lungs of mice that
325 were sensitized and challenged with OVA, whereas S100A8 or S100A9 knockdown markedly
326 reduced it (Fig. 3K). Furthermore, macrophages, lymphocytes, neutrophils, and eosinophils were
327 counted by Diff-Quik staining, and concentrations of IL-4, IL-13, TGF- β 1, TNF- α , and IFN- γ
328 were measured by ELISA. Most of them were significantly increased in the BALF from mice
329 sensitized and challenged with OVA ($p < 0.01$) (Fig. 3L-S) but the IFN- γ concentration was
330 decreased ($p < 0.01$) (Fig. 3T). S100A8 or S100A9 knockdown antagonized the OVA-induced
331 inflammatory response ($p < 0.01$) (Fig. 3L-T). In summary, S100A8/9 knockdown improved
332 respiratory function, lung tissue injury, and inflammation in mice sensitized and challenged with
333 OVA.

334

335 **4. S100A8/9 knockdown suppressed macrophage polarization in OVA-sensitized and 336 challenged mice**

337 Changes in glycolysis *in vivo*. Flow cytometry was used to detect macrophage polarization in the
338 BALF. The results showed that the proportions of M1 (CD86+) and M2 (CD206+) cells were
339 increased in mice sensitized and challenged with OVA, whereas S100A8 or S100A9 knockdown
340 decreased them ($p < 0.05$) (Fig. 4A, B). IHC was used to detect the expression of macrophage
341 biomarkers. The total macrophage biomarkers CD68, M1 macrophage biomarker IRF-5, and M2
342 macrophage biomarker YM-1 were measured, and their positive cells increased in OVA-
343 sensitized and challenged mice ($p < 0.01$) (Fig. 4C, D). However, S100A9 knockdown
344 significantly decreased these levels in OVA-sensitized and challenged mice ($p < 0.05$) (Fig. 4C,
345 D). Furthermore, the mRNA levels of IL-6, iNOS, Arg1, and IL-10 were determined using qRT-
346 PCR. Among these, IL-6 and iNOS are genes related to M1 macrophages, whereas Arg1 and IL-
347 10 are related to M1 macrophages (Zhu et al. 2015). They increased in OVA-sensitized
348 sensitized and challenged mice, whereas S100A8 or S100A9 knockdown decreased them, except
349 for IL-10, which showed the opposite trends ($p < 0.01$) (Fig. 4E-F).

350

351 **5. S100A8/9 knockdown inhibited glycolysis in the lung of OVA-sensitized and challenged 352 mice**

353 Serum lactic acid concentration was markedly increased in the OVA group. However, S100A8
354 and S100A9 knockdown inhibited it ($p < 0.01$) (Fig. 5A), suggesting that glycolysis was
355 inhibited. Pyruvate dehydrogenase (PDH), lactate dehydrogenase (LDH) A, and HK2 are key
356 enzymes involved in glycolysis (Pereverzeva et al. 2022). Their mRNAs increased in OVA-

357 sensitized and challenged mice, whereas S100A8 and S100A9 knockdown significantly
358 decreased their levels ($p < 0.01$) (Fig. 5A-D). Furthermore, we used Western blot to measure the
359 levels of LDHA, HK2, TLR4, MyD88, p-NF- κ B/NF- κ B, p-I κ B α /I κ B α , gasdermin D-N, and
360 cleaved-caspase-1/caspase-1. OVA-induced allergic asthma increased all levels, whereas
361 S100A8 and S100A9 knockdown decreased the levels in OVA-sensitized and challenged mice
362 ($p < 0.01$) (Fig. 5E-M).

363

364 **6. S100A9 overexpression had an adverse impact on respiratory function and lung tissue
365 while enhancing inflammation in ovalbumin-sensitized and challenged mice**

366 Evidence proved that the expression level of S100A8 is regulated by S100A9 (Hobbs et al.
367 2003). We found knockdown of S100A9 ameliorated injury in allergic mice and inhibited
368 glycolysis in macrophages and lung tissues. To clarify the ability of S100A9 to regulate
369 glycolysis, we used allergic asthmatic mice overexpressing S100A9 to observe the promotion of
370 glycolysis by S100A9 overexpression. The glycolysis inhibitor, 3-BP, can inhibit HK2 (Zhong et
371 al. 2022). Using 3-BP treatment, we explored the potential mechanisms by which S100A9
372 regulates glycolysis. S100A9 mRNA levels in the OVA + OE-S100A9 group were 2.94 times
373 higher than those in the OVA group, and 3-BP intervention did not affect the mRNA levels ($p <$
374 0.01) (Fig. 6A). Serum OVA-specific IgE in OVA-sensitized and challenged mice with the 3-BP
375 intervention was significantly decreased compared to that in the OVA group ($p < 0.01$), while
376 S100A9 overexpression markedly increased IgE compared to that in the OVA group ($p < 0.01$)
377 (Fig. 6B). Compared with the OVA group, TV, VC, EV, MV, FEV0.1, EIP, PEF, EF50, and
378 Cdyn in the OVA + 3-BP group were markedly increased, whereas S100A9 overexpression
379 increased them ($p < 0.05$) (Fig. 6C-K). Histological analysis indicated a decrease in peribronchial
380 inflammatory infiltrates in the lungs of OVA-sensitized and challenged mice with 3-BP
381 intervention, while S100A9 overexpression enhanced lung tissue damage (Fig. 6L). Furthermore,
382 in the BALF of the OVA + 3-BP group compared to that of the OVA group, macrophages,
383 lymphocytes, neutrophils, eosinophils, and the concentrations of IL-4, IL-13, TGF- β 1, and TNF-
384 α were significantly decreased ($p < 0.01$), while their levels were increased in OVA-sensitized
385 and challenged mice with S100A9 overexpression ($p < 0.01$) (Fig. 6M-T). However, compared to
386 the OVA group, IFN- γ concentration was increased in the BALF of the OVA + 3-BP group,
387 whereas it was decreased in the OE-S100A9 group ($p < 0.01$) (Fig. 6U). Furthermore, 3-BP
388 treatment antagonized the effects of S100A9 overexpression on inflammation. S100A9
389 overexpression had detrimental effects on respiratory function and lungs in OVA-sensitized and -
390 challenged mice, while also enhancing inflammation by promoting glycolysis.

391

392 **7. S100A9 overexpression promoted macrophage polarization in ovalbumin-sensitized and
393 challenged mice**

394 Flow cytometry results showed that the proportion of M1 (CD86+) and M2 (CD206+)
395 macrophages was decreased in OVA-induced allergic asthma mice with 3-BP intervention,
396 whereas they increased in OVA-sensitized and challenged mice with S100A9 overexpression ($p <$

397 0.01) (Fig. 7A, B). Immunohistochemistry was performed to observe the expression levels of
398 macrophage biomarkers. CD68 is a macrophage biomarker, IRF-5 is an M1 macrophage
399 biomarker, and YM-1 is an M2 macrophage biomarker. CD68, IRF-5, and YM-1 positive cells
400 were all decreased in OVA-sensitized and challenged mice with 3-BP administration, but were
401 significantly increased after S100A9 overexpression ($p < 0.01$) (Fig. 7D). In the lungs, IL-6,
402 iNOS, and Arg1 mRNA levels decreased in OVA-sensitized and challenged mice with 3-BP
403 intervention and increased in OVA-sensitized and challenged mice with S100A9 overexpression,
404 whereas IL-10 showed the opposite trend. Furthermore, results showed that 3-BP intervention
405 antagonized the stimulatory effects of S100A9 overexpression on macrophage polarization in
406 OVA-sensitized and -challenged mice ($p < 0.01$) (Fig. 7).

407

408 **8. S100A9 overexpression inhibited glycolysis in the lung of ovalbumin-sensitized and 409 challenged mice**

410 Compared to the OVA group, the serum lactic acid concentration in OVA-sensitized and -
411 challenged mice was inhibited by 3-BP intervention and were increased in the OVA + OE-
412 S100A9 group ($p < 0.01$) (Fig. 8A). PDH, LDH, and HK2, the key enzymes of glycolysis, were
413 measured by qRT-PCR and were decreased in mice post-OVA challenge with 3-BP intervention,
414 whereas they were increased in OVA-sensitized and challenged mice by S100A9 overexpression
415 ($p < 0.05$) (Fig. 8B-D). The expression levels of LDHA, HK2, TLR4, MyD88, p-NF- κ B/NF- κ B,
416 p-I κ B α /I κ B α , gasdermin D-N, and cleaved-caspase-1/caspase-1 levels were measured by
417 Western blot. Compared to the OVA-sensitized and challenged mice, they all decreased in the
418 OVA + 3-BP group and increased in the OVA + OE-S100A9 group ($p < 0.01$) (Fig. 8E-L).
419 Additionally, 3-BP antagonized the promotion of S100A9 overexpression in serum lactic acid,
420 glycolysis-related enzymes, and genes.

421

422 **Discussion**

423 Allergic asthma is a chronic lung disease characterized by reversible airway obstruction resulting
424 in airflow limitation, as well as physiological symptoms such as wheezing, coughing, and
425 changes in the bronchial structure (Hough et al. 2020). Macrophage polarization plays an
426 important role in the development of allergic asthma. The *in vivo* results of our study
427 demonstrated that the knockdown of S100A8 or S100A9 inhibited M1 and M2 macrophage
428 polarization and improved respiratory function and lung injury in mice with allergic asthma. In
429 particular, S100A9 overexpression exacerbates lung injury and inflammation in allergic asthma.
430 Additionally, the glycolysis inhibitor 3-BP (HK2 inhibitor) antagonized S100A9 overexpression,
431 effects, suggesting that the regulation of glycolysis plays a critical role in the involvement of
432 S100A9 in allergic asthma and HK2 might be a target of S100A9. The OVA-induced asthma mouse
433 model is a classic allergic asthma model that usually shows decreased IFN- γ levels (Lertnimitphun et al.
434 2021). IFN- γ is mainly secreted by T lymphocytes, macrophages, mucosal epithelial cells, or natural killer
435 cells (Piao et al. 2023; Ding et al. 2022). IFN- γ can also activate M1 macrophages (Fu et al. 2023),
436 which contradicts the results we observed *in vivo*, suggesting IFN- γ levels in BALF are not

437 dependent on macrophages. Knockdown of S100A8 or S100A9 increased IFN- γ levels,
438 suggesting that S100A proteins may be involved in immune imbalance. This could be an
439 interesting direction for future research.

440 We found that S100A8 and S100A9 knockdown inhibited M1 and M2 macrophage polarization.
441 M1 macrophages express pro-inflammatory factors, such as IL-6, IL-1 β , and TNF- α , as well as
442 iNOS, and play a role in recruiting and activating other immune cells (Saradna et al. 2018). In
443 contrast, M2 macrophages express Ym1, Arg1, CD206, IL-10, TGF- β , and other anti-
444 inflammatory factors (Müller et al. 2007; Dewhurst et al. 2017). There are four subtypes of M2
445 macrophages which express different cytokines, chemokines, and growth factors, and have
446 varying functions in inflammation (Murray et al. 2014; Röszer 2015). Among them, M2a
447 macrophages are associated with the lung allergic inflammation that induced by Th2 polarizing
448 cytokines (IL-4 or IL-13) to overexpression of IL-10, TGF- β , and inflammatory chemokines;
449 moreover, M2b macrophages are facilitated by immune complexes and have been demonstrated
450 to play an important role in the Th2 immune response (Ross et al. 2021). Additionally, the
451 subtype M2b macrophages exhibit a phenotype similar to that of M1 macrophages (IL-1 β
452 activates and releases TNF- α), simultaneously secreting high levels of IL-10 (Kang et al. 2022).
453 However, exosomes derived from M2b macrophages antagonize colitis (Yang et al. 2019). The
454 role of the M2b macrophages in allergic asthma is not yet clear. However, IL-10 is an anti-
455 inflammatory cytokine that ensures mitochondrial integrity and inhibits cellular glycolysis levels
456 (Ip et al. 2017). Low levels of IL-10 or few M2b macrophages may be involved in regulating
457 macrophage metabolism and promoting the development of allergic asthma. Further experiments
458 are needed to explore the macrophage phenotype associated with IL-10 expression. Macrophage
459 polarization is a complex process involving cellular activities. The pro-inflammation effect of
460 M1 macrophages and the anti-inflammation effect of M2 macrophages are well known. Recent
461 evidence suggests that M1 and M2 macrophages can coexist, with changes in cellular
462 metabolism to regulate their polarization (Tang et al. 2023). An OVA-induced macrophage
463 injury model showed the coexistence of M1 and M2 macrophages (Wo et al. 2023), indicating
464 that macrophage polarization may promote OVA-induced lung damage. We also found that
465 knockdown of S100A8 or S100A9 inhibited lactate acid and LDHA levels. Studies have shown
466 that increased glycolysis generally manifests as increased lactate acid and LDHA (Zhang et al.
467 2023). Our study highlighted the potential of inhibiting S100A8 and S100A9 to ameliorate
468 allergic asthma by stabilizing macrophage polarization and inhibiting glycolysis.
469 In the last three years, immunometabolic studies on allergies have reported that asthma is
470 associated with increased aerobic glycolysis (Goretzki et al. 2023). Studies have found that
471 serum lactate acid levels in patients with asthma are significantly higher than those in healthy
472 controls, indicating the presence of glycolytic reprogramming of glycolysis in asthma
473 (Ostroukhova et al. 2012). The competitive glucose inhibitor 2-DG inhibits Arg2 expression *in*
474 *vitro* (Svedberg et al. 2019). The knockdown of S100A8 or S100A9 inhibited glycolysis and M2
475 polarization, which is consistent with previous findings and further highlights the importance of
476 glycolysis in macrophage polarization.

477 HK2 is a key enzyme involved in glucose phosphorylation (the first step in the glucose
478 metabolism pathway), and evidence has shown that inhibiting HK2 transcription reduces
479 glycolysis in macrophages (Yang et al. 2022; Yuan et al. 2022). S100A8 and S100A9
480 knockdown inhibited HK2 and GAPDH expression, suggesting that S100A8 and S100A9 are
481 involved in the regulation of glycolysis in allergic asthmatic macrophages. S100A8 is an
482 endogenous ligand for TLR4, which has been shown to induce intracellular translocation of
483 MyD88 as well as NF- κ B activation to promote the elevation of TNF- α levels (Vogl et al. 2007).
484 Additionally, LPS-induced TLR4 activation regulates metabolic fluxes, which is mainly
485 dominated by the enhancement of histone acetylation resulting from the production of acetyl-
486 CoA from glucose (Lauterbach et al. 2019). Early TLR4-driven aerobic glycolysis was initiated
487 by overlapping and redundant contributions of MyD88- and TRIF-dependent signaling
488 pathways, as well as downstream mTOR activation (Fensterheim et al. 2018). An increase in
489 glucose uptake and accelerated glycolytic flux promote mitochondrial citrate production and
490 mitochondrial citrate can be converted to acetyl-CoA by ACLY (Granchi 2018). The
491 TLR4/MyD88/TRIF/NF- κ B signaling pathway and ACLY activity were inhibited in OVA-
492 induced MH-S cells with knockdown of S100A8 or S100A9 and allergic asthma mice,
493 suggesting that knockdown of S100A8 or S100A9 inhibits glycolysis by suppressing the
494 TLR4/MyD88/TRIF/NF- κ B signaling pathway. LPS intervention antagonizes the effects of
495 S100A8 or S100A9 knockdown in OVA-induced MH-S cells. In addition, 3-BP, an inhibitor of
496 HK-II, antagonized the effects of S100A9 overexpression, suggesting that HK-II is a key gene
497 involved in the S100A8 and S100A9 regulation of glycolysis in mice with allergic asthma, which
498 warrants further investigation. In addition, we observed the effect of S100A8 or S100A9
499 knockdown on pyroptosis. The inhibition of macrophage pyroptosis is usually beneficial in
500 reducing inflammation (Sun et al. 2021). However, studies have shown that inhibition of
501 glycolysis inhibits pyroptosis, and there is still a lack of research on the role and mechanism of
502 macrophage pyroptosis in allergic asthma (Zasłona et al. 2020; Aki et al. 2022).
503 Our study has certain limitations owing to the complexity of macrophage polarization and
504 function. However, research on macrophage subtypes remains insufficient. Further investigation
505 is necessary to differentiate the effects of S100A8/A9 on the proportion of macrophage subtypes
506 in allergic asthma. Our study used only OVA to construct models *in vitro* and *in vivo*. Although
507 OVA was used to create a classical allergic asthma model, it could not generalize all clinical
508 manifestations; therefore, future validation experiments on multiple allergic asthma models are
509 needed to strengthen our hypothesis. Furthermore, as basic research, this result cannot be
510 generalized to clinical practice and still requires a substantial number of animal experiments and
511 clinical data. Overall, our work provides new ideas and directions for the treatment of allergic
512 asthma.

513

514 **Conclusions**

515 Our study highlights that S100A8 and S100A9 play critical roles in the pathogenesis of allergic
516 asthma by promoting macrophage perturbation and glycolysis through the TLR4/MyD88/NF- κ B

517 signaling pathway. Inhibition of S100A8 and S100A9 may be a potential therapeutic strategy for
518 allergic asthma. Further basic and human studies are required to explore the underlying
519 mechanisms.

520

521 **Ethics statement**

522 Animal experiments were reviewed and regulated by the Animal Experimentation Ethics
523 Committee of Zhejiang Eyong Pharmaceutical Research and Development Center.

524

525 **Acknowledgements**

526 Not applicable

527

528 **References**

529 Aki T, Funakoshi T, Unuma K, Uemura K (2022) Inverse regulation of GSDMD and GSDME gene
530 expression during LPS-induced pyroptosis in RAW264.7 macrophage cells. *Apoptosis* 27 (1-
531 2):14-21.<https://doi.org/10.1007/s10495-022-01708-1>

532 Alhouayek M, Masquelier J, Cani PD, Lambert DM, Muccioli GG (2013) Implication of the anti-
533 inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage
534 activation and inflammation by ABHD6. *Proc Natl Acad Sci U S A* 110 (43):17558-
535 17563.<https://doi.org/10.1073/pnas.1314017110>

536 Ciesielska A, Matyjek M, Kwiatkowska K (2021) TLR4 and CD14 trafficking and its influence on LPS-
537 induced pro-inflammatory signaling. *Cell Mol Life Sci* 78 (4):1233-
538 1261.<https://doi.org/10.1007/s00018-020-03656-y>

539 De Jesus A, Keyhani-Nejad F, Pusec CM, Goodman L, Geier JA, Stoolman JS, Stanczyk PJ, Nguyen T,
540 Xu K, Suresh KV, Chen Y, Rodriguez AE, Shapiro JS, Chang HC, Chen C, Shah KP, Ben-Sahra
541 I, Layden BT, Chandel NS, Weinberg SE, Ardehali H (2022) Hexokinase 1 cellular localization
542 regulates the metabolic fate of glucose. *Mol Cell* 82 (7):1261-
543 1277.e1269.<https://doi.org/10.1016/j.molcel.2022.02.028>

544 Decaesteker T, Bos S, Lorent N, Everaerts S, Vanoirbeek J, Bullens D, Dupont LJ (2022) Elevated serum
545 calprotectin (S100A8/A9) in patients with severe asthma. *J Asthma* 59 (6):1110-
546 1115.<https://doi.org/10.1080/02770903.2021.1914649>

547 Dewhurst JA, Lea S, Hardaker E, Dungwa JV, Ravi AK, Singh D (2017) Characterisation of lung
548 macrophage subpopulations in COPD patients and controls. *Sci Rep* 7
549 (1):7143.<https://doi.org/10.1038/s41598-017-07101-2>

550 Ding H, Wang G, Yu Z, Sun H, Wang L (2022) Role of interferon-gamma (IFN- γ) and IFN- γ receptor 1/2
551 (IFN γ R1/2) in regulation of immunity, infection, and cancer development: IFN- γ -dependent or
552 independent pathway. *Biomed Pharmacother*
553 155:113683.<https://doi.org/10.1016/j.biopha.2022.113683>

554 Draijer C, Florez-Sampedro L, Reker-Smit C, Post E, van Dijk F, Melgert BN (2022) Explaining the
555 polarized macrophage pool during murine allergic lung inflammation. *Front Immunol*
556 13:1056477.<https://doi.org/10.3389/fimmu.2022.1056477>

557 El Kasmi KC, Stenmark KR (2015) Contribution of metabolic reprogramming to macrophage plasticity
558 and function. *Semin Immunol* 27 (4):267-275.<https://doi.org/10.1016/j.smim.2015.09.001>

559 Fang Y, Shen ZY, Zhan YZ, Feng XC, Chen KL, Li YS, Deng HJ, Pan SM, Wu DH, Ding Y (2019)
560 CD36 inhibits β -catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress
561 colorectal tumorigenesis. *Nat Commun* 10 (1):3981.<https://doi.org/10.1038/s41467-019-11662-3>

562 Fensterheim BA, Young JD, Luan L, Kleinbard RR, Stothers CL, Patil NK, McAtee-Pereira AG, Guo Y,
563 Trenary I, Hernandez A, Fults JB, Williams DL, Sherwood ER, Bohannon JK (2018) The TLR4

564 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic
565 Reprogramming of Macrophage Metabolism. *J Immunol* 200 (11):3777-
566 3789. <https://doi.org/10.4049/jimmunol.1800085>

567 Fu B, Xiong Y, Sha Z, Xue W, Xu B, Tan S, Guo D, Lin F, Wang L, Ji J, Luo Y, Lin X, Wu H (2023)
568 SEPTIN2 suppresses an IFN- γ -independent, proinflammatory macrophage activation pathway.
569 *Nat Commun* 14 (1):7441. <https://doi.org/10.1038/s41467-023-43283-2>

570 Goretzki A, Zimmermann J, Rainer H, Lin YJ, Schülke S (2023) Immune Metabolism in TH2 Responses:
571 New Opportunities to Improve Allergy Treatment - Disease-Specific Findings (Part 1). *Curr*
572 *Allergy Asthma Rep* 23 (1):29-40. <https://doi.org/10.1007/s11882-022-01057-8>

573 Granchi C (2018) ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of
574 glucose and lipid metabolism. *Eur J Med Chem* 157:1276-
575 1291. <https://doi.org/10.1016/j.ejmech.2018.09.001>

576 Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C, Henderson R, Robinson MJ, Hogg N
577 (2003) Myeloid cell function in MRP-14 (S100A9) null mice. *Mol Cell Biol* 23 (7):2564-
578 2576. <https://doi.org/10.1128/mcb.23.7.2564-2576.2003>

579 Holt PG (1986) Down-regulation of immune responses in the lower respiratory tract: the role of alveolar
580 macrophages. *Clin Exp Immunol* 63 (2):261-270

581 Hough KP, Curtiss ML, Blain TJ, Liu RM, Trevor J, Deshane JS, Thannickal VJ (2020) Airway
582 Remodeling in Asthma. *Front Med (Lausanne)* 7:191. <https://doi.org/10.3389/fmed.2020.00191>

583 Ioachimescu OC, Desai NS (2019) Nonallergic Triggers and Comorbidities in Asthma Exacerbations and
584 Disease Severity. *Clin Chest Med* 40 (1):71-85. <https://doi.org/10.1016/j.ccm.2018.10.005>

585 Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R (2017) Anti-inflammatory effect of IL-10
586 mediated by metabolic reprogramming of macrophages. *Science* 356 (6337):513-
587 519. <https://doi.org/10.1126/science.aal3535>

588 Kang H, Bang JY, Mo Y, Shin JW, Bae B, Cho SH, Kim HY, Kang HR (2022) Effect of *Acinetobacter*
589 *lwoffii* on the modulation of macrophage activation and asthmatic inflammation. *Clin Exp*
590 *Allergy* 52 (4):518-529. <https://doi.org/10.1111/cea.14077>

591 Kelly B, O'Neill LA (2015) Metabolic reprogramming in macrophages and dendritic cells in innate
592 immunity. *Cell Res* 25 (7):771-784. <https://doi.org/10.1038/cr.2015.68>

593 Lauterbach MA, Hanke JE, Serefidou M, Mangan MSJ, Kolbe CC, Hess T, Rothe M, Kaiser R, Hoss F,
594 Gehlen J, Engels G, Kreutzenbeck M, Schmidt SV, Christ A, Imhof A, Hiller K, Latz E (2019)
595 Toll-like Receptor Signaling Rewires Macrophage Metabolism and Promotes Histone Acetylation
596 via ATP-Citrate Lyase. *Immunity* 51 (6):997-
597 1011.e1017. <https://doi.org/10.1016/j.jimmuni.2019.11.009>

598 Lee YG, Hong J, Lee PH, Lee J, Park SW, Kim D, Jang AS (2020) Serum Calprotectin Is a Potential
599 Marker in Patients with Asthma. *J Korean Med Sci* 35
600 (43):e362. <https://doi.org/10.3346/jkms.2020.35.e362>

601 Lee YG, Jeong JJ, Nyenhuis S, Berdyshev E, Chung S, Ranjan R, Karpurapu M, Deng J, Qian F, Kelly
602 EA, Jarjour NN, Ackerman SJ, Natarajan V, Christman JW, Park GY (2015) Recruited alveolar
603 macrophages, in response to airway epithelial-derived monocyte chemoattractant protein 1/CCl2,
604 regulate airway inflammation and remodeling in allergic asthma. *Am J Respir Cell Mol Biol* 52
605 (6):772-784. <https://doi.org/10.1165/rcmb.2014-0255OC>

606 Lertnimitphun P, Zhang W, Fu W, Yang B, Zheng C, Yuan M, Zhou H, Zhang X, Pei W, Lu Y, Xu H
607 (2021) Safranal Alleviated OVA-Induced Asthma Model and Inhibits Mast Cell Activation. *Front*
608 *Immunol* 12:585595. <https://doi.org/10.3389/fimmu.2021.585595>

609 Li C, Deng C, Zhou T, Hu J, Dai B, Yi F, Tian N, Jiang L, Dong X, Zhu Q, Zhang S, Cui H, Cao L,
610 Shang Y (2021a) MicroRNA-370 carried by M2 macrophage-derived exosomes alleviates asthma
611 progression through inhibiting the FGF1/MAPK/STAT1 axis. *Int J Biol Sci* 17 (7):1795-
612 1807. <https://doi.org/10.7150/ijbs.59715>

613 Li Y, Zhang L, Ren P, Yang Y, Li S, Qin X, Zhang M, Zhou M, Liu W (2021b) Qing-Xue-Xiao-Zhi
614 formula attenuates atherosclerosis by inhibiting macrophage lipid accumulation and inflammatory

615 response via TLR4/MyD88/NF- κ B pathway regulation. *Phytomedicine*
616 93:153812.<https://doi.org/10.1016/j.phymed.2021.153812>

617 Morsi AA, Faruk EM, Mogahed MM, Baioumy B, Hussein AYA, El-Shafey RS, Mersal EA,
618 Abdelmoneim AM, Alanazi MM, Elshazly AME (2023) Modeling the Effects of Cypermethrin
619 Toxicity on Ovalbumin-Induced Allergic Pneumonitis Rats: Macrophage Phenotype
620 Differentiation and p38/STAT6 Signaling Are Candidate Targets of Pirfenidone Treatment. *Cells*
621 12 (7).<https://doi.org/10.3390/cells12070994>

622 Müller U, Stenzel W, Köhler G, Werner C, Polte T, Hansen G, Schütze N, Straubinger RK, Blessing M,
623 McKenzie AN, Brombacher F, Alber G (2007) IL-13 induces disease-promoting type 2
624 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary
625 infection of mice with *Cryptococcus neoformans*. *J Immunol* 179 (8):5367-
626 5377.<https://doi.org/10.4049/jimmunol.179.8.5367>

627 Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB,
628 Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP,
629 Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA
630 (2014) Macrophage activation and polarization: nomenclature and experimental guidelines.
631 *Immunity* 41 (1):14-20.<https://doi.org/10.1016/j.jimmuni.2014.06.008>

632 Ostroukhova M, Goplen N, Karim MZ, Michalec L, Guo L, Liang Q, Alam R (2012) The role of low-
633 level lactate production in airway inflammation in asthma. *Am J Physiol Lung Cell Mol Physiol*
634 302 (3):L300-307.<https://doi.org/10.1152/ajplung.00221.2011>

635 Padem N, Saltoun C (2019) Classification of asthma. *Allergy Asthma Proc* 40 (6):385-
636 388.<https://doi.org/10.2500/aap.2019.40.4253>

637 Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE, van den Bosch
638 MW, Quinn SR, Domingo-Fernandez R, Johnston DG, Jiang JK, Israelsen WJ, Keane J, Thomas
639 C, Clish C, Vander Heiden M, Xavier RJ, O'Neill LA (2015) Pyruvate kinase M2 regulates Hif-
640 1 α activity and IL-1 β induction and is a critical determinant of the warburg effect in LPS-
641 activated macrophages. *Cell Metab* 21 (1):65-80.<https://doi.org/10.1016/j.cmet.2014.12.005>

642 Pereverzeva L, van Linge CCA, Schuurman AR, Klarenbeek AM, Ramirez Moral I, Otto NA, Peters-
643 Sengers H, Butler JM, Schomakers BV, van Weeghel M, Houtkooper RH, Wiersinga WJ, Bonta
644 PI, Annema JT, de Vos AF, van der Poll T (2022) Human alveolar macrophages do not rely on
645 glucose metabolism upon activation by lipopolysaccharide. *Biochim Biophys Acta Mol Basis Dis*
646 1868 (10):166488.<https://doi.org/10.1016/j.bbadiis.2022.166488>

647 Piao CH, Fan Y, Nguyen TV, Song CH, Kim HT, Chai OH (2023) PM2.5 exposure regulates
648 Th1/Th2/Th17 cytokine production through NF- κ B signaling in combined allergic rhinitis and
649 asthma syndrome. *Int Immunopharmacol*
650 119:110254.<https://doi.org/10.1016/j.intimp.2023.110254>

651 Quoc QL, Choi Y, Thi Bich TC, Yang EM, Shin YS, Park HS (2021) S100A9 in adult asthmatic patients:
652 a biomarker for neutrophilic asthma. *Exp Mol Med* 53 (7):1170-
653 1179.<https://doi.org/10.1038/s12276-021-00652-5>

654 Rabe APJ, Loke WJ, Gurjar K, Brackley A, Lucero-Prisno Iii DE (2023) Global Burden of Asthma, and
655 Its Impact on Specific Subgroups: Nasal Polyps, Allergic Rhinitis, Severe Asthma, Eosinophilic
656 Asthma. *J Asthma Allergy* 16:1097-1113.<https://doi.org/10.2147/jaa.S418145>

657 Ross EA, Devitt A, Johnson JR (2021) Macrophages: The Good, the Bad, and the Gluttony. *Front
658 Immunol* 12:708186.<https://doi.org/10.3389/fimmu.2021.708186>

659 Röszer T (2015) Understanding the Mysterious M2 Macrophage through Activation Markers and Effector
660 Mechanisms. *Mediators Inflamm* 2015:816460.<https://doi.org/10.1155/2015/816460>

661 Santarsiero A, Convertini P, Todisco S, Pierri CL, De Grassi A, Williams NC, Iacobazzi D, De Stefano
662 G, O'Neill LAJ, Infantino V (2021) ACLY Nuclear Translocation in Human Macrophages Drives
663 Proinflammatory Gene Expression by NF- κ B Acetylation. *Cells* 10
664 (11).<https://doi.org/10.3390/cells10112962>

665 Saradna A, Do DC, Kumar S, Fu QL, Gao P (2018) Macrophage polarization and allergic asthma. *Transl
666 Res* 191:1-14.<https://doi.org/10.1016/j.trsl.2017.09.002>

667 Schatz M, Rosenwasser L (2014) The allergic asthma phenotype. *J Allergy Clin Immunol Pract* 2 (6):645-
668 648; quiz 649.<https://doi.org/10.1016/j.jaip.2014.09.004>

669 Sun S, Xu X, Liang L, Wang X, Bai X, Zhu L, He Q, Liang H, Xin X, Wang L, Lou C, Cao X, Chen X,
670 Li B, Wang B, Zhao J (2021) Lactic Acid-Producing Probiotic *Saccharomyces cerevisiae*
671 Attenuates Ulcerative Colitis via Suppressing Macrophage Pyroptosis and Modulating Gut
672 Microbiota. *Front Immunol* 12:777665.<https://doi.org/10.3389/fimmu.2021.777665>

673 Svedberg FR, Brown SL, Krauss MZ, Campbell L, Sharpe C, Clausen M, Howell GJ, Clark H, Madsen J,
674 Evans CM, Sutherland TE, Ivens AC, Thornton DJ, Grencis RK, Hussell T, Cunoosamy DM,
675 Cook PC, MacDonald AS (2019) The lung environment controls alveolar macrophage
676 metabolism and responsiveness in type 2 inflammation. *Nat Immunol* 20 (5):571-
677 580.<https://doi.org/10.1038/s41590-019-0352-y>

678 Tang X, Li Y, Zhao J, Liang L, Zhang K, Zhang X, Yu H, Du H (2023) Heme oxygenase-1 increases
679 intracellular iron storage and suppresses inflammatory response of macrophages by inhibiting M1
680 polarization. *Metalloomics*.<https://doi.org/10.1093/mto/mfad062>

681 Vogl T, Leukert N, Barczyk K, Strupat K, Roth J (2006) Biophysical characterization of S100A8 and
682 S100A9 in the absence and presence of bivalent cations. *Biochim Biophys Acta* 1763 (11):1298-
683 1306.<https://doi.org/10.1016/j.bbamer.2006.08.028>

684 Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll
685 T, Sorg C, Roth J (2007) MRP8 and MRP14 are endogenous activators of Toll-like receptor 4,
686 promoting lethal, endotoxin-induced shock. *Nat Med* 13 (9):1042-
687 1049.<https://doi.org/10.1038/nm1638>

688 Wang Y, Zhang D, Liu T, Wang JF, Wu JX, Zhao JP, Xu JW, Zhang JT, Dong L (2021) FSTL1
689 aggravates OVA-induced inflammatory responses by activating the NLRP3/IL-1 β signaling
690 pathway in mice and macrophages. *Inflamm Res* 70 (7):777-787.<https://doi.org/10.1007/s00011-021-01475-w>

691 Wo B, Du C, Yang Y, Qi H, Liang Z, He C, Yao F, Li X (2023) Human placental extract regulates
692 polarization of macrophages via IRGM/NLRP3 in allergic rhinitis. *Biomed Pharmacother*
693 160:114363.<https://doi.org/10.1016/j.biopha.2023.114363>

694 Xu Y, Cui K, Li J, Tang X, Lin J, Lu X, Huang R, Yang B, Shi Y, Ye D, Huang J, Yu S, Liang X (2020)
695 Melatonin attenuates choroidal neovascularization by regulating macrophage/microglia
696 polarization via inhibition of RhoA/ROCK signaling pathway. *J Pineal Res* 69
697 (1):e12660.<https://doi.org/10.1111/jpi.12660>

698 Yang R, Liao Y, Wang L, He P, Hu Y, Yuan D, Wu Z, Sun X (2019) Exosomes Derived From M2b
699 Macrophages Attenuate DSS-Induced Colitis. *Front Immunol*
700 10:2346.<https://doi.org/10.3389/fimmu.2019.02346>

701 Yang Y, Fu X, Liu R, Yan L, Yang Y (2022) Exploring the prognostic value of HK3 and its association
702 with immune infiltration in glioblastoma multiforme. *Front Genet*
703 13:1033572.<https://doi.org/10.3389/fgene.2022.1033572>

704 Yuan Y, Fan G, Liu Y, Liu L, Zhang T, Liu P, Tu Q, Zhang X, Luo S, Yao L, Chen F, Li J (2022) The
705 transcription factor KLF14 regulates macrophage glycolysis and immune function by inhibiting
706 HK2 in sepsis. *Cell Mol Immunol* 19 (4):504-515.<https://doi.org/10.1038/s41423-021-00806-5>

707 Zasłona Z, Flis E, Wilk MM, Carroll RG, Palsson-McDermott EM, Hughes MM, Diskin C, Banahan K,
708 Ryan DG, Hooftman A, Misiak A, Kearney J, Lochnit G, Bertrams W, Greulich T, Schmeck B,
709 McElvaney OJ, Mills KHG, Lavelle EC, Wygrecka M, Creagh EM, O'Neill LAJ (2020) Caspase-
710 11 promotes allergic airway inflammation. *Nat Commun* 11
711 (1):1055.<https://doi.org/10.1038/s41467-020-14945-2>

712 Zhang J, Yuan Z, Li X, Wang F, Wei X, Kang Y, Mo C, Jiang J, Liang H, Ye L (2023) Activation of the
713 JNK/COX-2/HIF-1 α axis promotes M1 macrophage via glycolytic shift in HIV-1 infection. *Life
714 Sci Alliance* 6 (12).<https://doi.org/10.26508/lsa.202302148>

715

716 Zhong J, Lu S, Jia X, Li Q, Liu L, Xie P, Wang G, Lu M, Gao W, Zhao T, Wang Q, Su W, Li N (2022)
717 Role of endoplasmic reticulum stress in apoptosis induced by HK2 inhibitor and its potential as a
718 new drug combination strategy. *Cell Stress Chaperones* 27 (3):273-
719 283.<https://doi.org/10.1007/s12192-022-01267-z>

720 Zhong Y, Huang T, Huang J, Quan J, Su G, Xiong Z, Lv Y, Li S, Lai X, Xiang Y, Wang Q, Luo L, Gao
721 X, Shao Y, Tang J, Lai T (2023) The HDAC10 instructs macrophage M2 program via
722 deacetylation of STAT3 and promotes allergic airway inflammation. *Theranostics* 13 (11):3568-
723 3581.<https://doi.org/10.7150/thno.82535>

724 Zhu L, Zhao Q, Yang T, Ding W, Zhao Y (2015) Cellular metabolism and macrophage functional
725 polarization. *Int Rev Immunol* 34 (1):82-100.<https://doi.org/10.3109/08830185.2014.969421>

726

Figure 1

Figure 1 S100A8/9 knockdown inhibited polarization and pyroptosis of mouse alveolar macrophages with ovalbumin intervention.

Mouse alveolar macrophages (MH-S cells) treated with S100A8, S100A9, or lipopolysaccharide (LPS) were incubated with 40 μ M ovalbumin (OVA) for 8 h to establish alveolar macrophage inflammation models. MH-S cells were divided into six groups ($n=3$ per group): control, OVA + sh-NC, OVA + S100A8, OVA + S100A8, OVA + S100A9, OVA + S100A8 + LPS, and OVA + S100A9 + LPS. In the cell supernatant, the concentrations of IL-1 β (A), IL-6 (B), and TNF- α (C) were measured by ELISA. In MH-S cells treated with OVA, IL-1 β (D) and IL-6 (E) mRNA levels were increased, but IL-10 (F) mRNA was decreased. In OVA-induced MH-S cells, the knockdown of S100A8 or S100A9 decreased the concentration and mRNA levels of IL-1 β and IL-6, increased IL-10, and inhibited the mRNA expression of iNOS (M1 macrophage biomarker) (G), Arg1 (H), and Fizz1 (M2 macrophage biomarker) (I). All mRNAs were detected using quantitative real-time PCR. Mouse alveolar macrophage polarization (J and K) and pyroptosis (L and M) were analyzed by flow cytometry. In the OVA group, the proportion of M1 (CD86+) and M2 (CD206+) cells increased, whereas S100A8 and S100A9 knockdown inhibited this increase. Additionally, LPS intervention antagonized the effects of S100A8 and S100A9 knockdown in the OVA-induced MH-S cell injury models. (mean \pm standard deviation) ** $p<0.01$ compared to control group; # $p<0.05$, ## $p<0.01$ compared to OVA group; ^ $p<0.05$, ^ $p<0.01$ compared to OVA + sh-S100A8 group; + $p<0.05$, ++ $p<0.01$ compared to OVA + sh-S100A8 group.




Figure 2

Figure 2 S100A8/9 knockdown inhibited glycolysis of mouse alveolar macrophages with ovalbumin intervention.

Mouse alveolar macrophages (MH-S cells) were divided into six groups ($n=3$ per group), including control, ovalbumin (OVA) + sh-NC, OVA + S100A8, OVA + S100A8, OVA + S100A9, OVA + S100A8 + LPS, and OVA + S100A9 + LPS groups. Lactic acid concentration (A) in cell supernatant was measured using a spectrophotometer. (B, C) In MH-S cells, concentration of phosphofructokinase (PFK) and hexokinase (HK) was measured using a spectrophotometer; they were increased in OVA group and can be inhibited by S100A8 or S100A9 knockdown. LPS intervention antagonist S100A8 or S100A9 knockdown's effect. (D-G) Glycolysis-related genes, GAPDH, HK2, LDHA, and PDH mRNA were detected by quantitative real-time PCR. They were a significant increase in MH-S cells with OVA induction, except for PDH, which showed decreased expression. S100A8 or S100A9 knockdown can inhibit GAPDH, HK2, and LDHA mRNA in OVA-induced MH-S cell injury models and increase PDH mRNA level, but LPS intervention can antagonist them. (H-L) Expression levels of TLR4, MyD88, TRIF, NF- κ B, and p-ACLY/ACLY in MH-S cells were detected by Western blot. In MH-S cells with OVA induction, they were increased and S100A8 or S100A9 knockdown decreased them, while LPS intervention partially antagonized the effects of S100A8 or S100A9 knockdown. (M) Protein bands of Western blot. (mean \pm standard deviation) $^{**}p<0.01$ compared to control group;

$^{##}p<0.01$ compared to OVA group; $^{\wedge}p<0.05$, $^{\wedge\wedge}p<0.01$ compared to OVA + sh-S100A8 group;

$^{+}p<0.05$, $^{++}p<0.01$ compared to OVA + sh-S100A8 group.




Figure 3

Figure 3 S100A8/9 knockdown improved respiratory function, lung tissue injury and inflammation of broncho-alveolar lavage fluid in ovalbumin-sensitized and challenged mice.

BALB/C mice with sh-NC, sh-S100A8, or S100A9 intervention were divided into negative control (NC), ovalbumin (OVA), OVA + sh-S100A8, and OVA + sh-S100A9 groups ($n=6$ per group). (A-I) Observation of respiratory function was based on the detection of tidal volume (TV), vital capacity (VC), expiratory volume (EV), minute ventilation volume (MV), forced expiratory volume in 0.1 seconds (FEV0.1), end inspiratory pause (EIP), peak expiratory flow (PEF), mid expiratory flow (EF50), and dynamic lung compliance (Cdyn) in OVA mice; they were decreased in OVA rats compared to NC rats and S100A8 or S100A9 knockdown in mice with OVA administration increased them. (J) Serum OVA-specific IgE was detected by ELISA; in OVA + sh-S100A8 and OVA + sh-S100A9 groups, IgE was decreased compared to OVA group. (K) Hematoxylin-eosin staining observed S100A8 or S100A9 knockdown improved lung tissue damage ($\times 400$, Scale bar = 50 μ m). The yellow arrow indicates representative inflammatory cell infiltration. In broncho-alveolar lavage fluid (BALF), (L) macrophages, (M) lymphocytes, (N) neutrophils, and (O) eosinophils were counted and were increased in OVA group. The concentration of IL-4 (P), IL-13 (Q), TGF- β 1 (R), TNF- α (S), and IFN- γ (T) in BALF were measured by ELISA. (mean \pm standard deviation) $^{**}p<0.01$ compared to NC group; $^{##}p<0.01$ compared to OVA group.




Figure 4

Figure 4 S100A8/9 knockdown suppressed macrophage polarization in ovalbumin-sensitized and challenged mice.

BALB/C mice with sh-NC, sh-S100A8, or S100A9 intervention were divided into negative control (NC), ovalbumin (OVA), OVA + sh-S100A8, and OVA + sh-S100A9 groups ($n=6$ per group). (A, B) Flow cytometry was used to detect polarization of macrophages in broncho-alveolar lavage fluid (BALF); the proportion of M1 (CD86+) and M2 (CD206+) cells was increased in mice with OVA administration, while in OVA-sensitized and challenged mice with S100A8 or S100A9 knockdown, they were decreased. (C) Immunohistochemistry was used to observe the expression levels of macrophage biomarkers. CD68 is a macrophage biomarker, IRF-5 is an M1 macrophage biomarker, and YM-1 is an M2 macrophage biomarker. (D) Statistic analysis of immunohistochemical image; CD68, IRF-5, and YM-1 positive cells were all increased in OVA-sensitized and challenged mice, but they were significantly decreased in OVA-sensitized sensitized and challenged mice with S100A9 knockdown. (E-H) The mRNA of IL-6, iNOS, Arg1 and IL-10 were detected by quantitative real-time PCR; they were increased in OVA-sensitized sensitized and challenged mice while S100A8 or S100A9 knockdown decreased them except for IL-10 which has opposite trends. (mean \pm standard deviation)

^{**} $p<0.01$ compared to NC group; [#] $p<0.05$, ^{##} $p<0.01$ compared to OVA group.




Figure 5

Figure 5 S100A8/9 knockdown inhibited glycolysis in ovalbumin-sensitized and challenged mouse lung tissue.

BALB/C mice with sh-NC, sh-S100A8, or S100A9 intervention were divided into negative control (NC), ovalbumin (OVA), OVA + sh-S100A8, and OVA + sh-S100A9 groups. (A) Serum lactic acid concentration was measured by using a spectrophotometer ($n=6$). (B-D) Pyruvate dehydrogenase (PDH), lactate dehydrogenase (LDH) A, and hexokinase (HK) 2 are key enzymes of glycolysis, and mRNA of them were increased in mice post-OVA-challenged, while they were decreased in OVA-sensitized and challenged mice by S100A8 and S100A9 knockdown ($n=3$). Quantitative real-time PCR is used for mRNA measurement. (E-M) Western blot is used for measurement of LDHA, HK2, TLR4, MyD88, p-NF- κ B/NF- κ B, p-I κ B α /I κ B α , Gasdermin D-N, and cleaved-caspase-1/caspase-1 levels ($n=3$). They were all increased by OVA-sensitized and challenged, and were decreased in OVA-sensitized and challenged mice by S100A8 and S100A9 knockdown. (mean \pm standard deviation) $^{**}p<0.01$ compared to NC group; $^{*}p<0.05$, $^{**}p<0.01$ compared to OVA group.




Figure 6

Figure 6 S100A9 overexpression had an adverse impact on respiratory function and lung tissue while enhancing inflammation in ovalbumin-sensitized and challenged mice.

Ovalbumin (OVA) sensitized BALB/C mice were divided into groups receiving 3-bromopyruvate (3-BP), S100A9 plasmid intervention, or both. The resulting groups were OVA, OVA + 3-BP, OVA + OE-S100A9, and OVA + OE-S100A9 + 3-BP ($n=6$ per group). (A) S100A9 mRNAs were detected by quantitative real-time PCR and were increased in OVA + OE-S100A9 and OVA + OE-S100A9 + 3-BP group. (B) Serum OVA-specific IgE was detected by ELISA; compared to OVA group, IgE was decreased in OVA + 3-BP groups and increased in OE-S100A9 group. (C-K) Observation of respiratory function was based on the detection of tidal volume (TV), vital capacity (VC), expiratory volume (EV), minute ventilation volume (MV), forced expiratory volume in 0.1 seconds (FEV0.1), end inspiratory pause (EIP), peak expiratory flow (PEF), mid expiratory flow (EF50), and dynamic lung compliance (Cdyn) in OVA mice; they were increased in OVA + 3-BP group compared to OVA group and S100A9 overexpression in mice with OVA administration decreased them. (L) Hematoxylin-eosin staining observed S100A9 overexpression enhanced lung tissue damage ($\times 400$, Scale bar = 50 μ m) while 3-BP can antagonize it. The yellow arrow indicates representative inflammatory cell infiltration. In broncho-alveolar lavage fluid from OVA-sensitized and challenged mice, (M) macrophages, (N) lymphocytes, (O) neutrophils, and (P) eosinophils were counted. (Q-U) Concentration of IL-4, IL-13, TGF- β 1, TNF- α and IFN- γ in broncho-alveolar lavage fluid was measured by ELISA. Inflammatory cells and cytokines were decreased in OVA + 3-BP group, but they were increased in OVA + OE-S100A9 group. In addition, 3-BP can antagonize the effect of S100A9 overexpression. (mean \pm standard deviation) $^*p < 0.05$, $^{**}p < 0.01$ compared to OVA group; $^+p < 0.05$, $^{++}p < 0.01$ compared to OVA + OE-S100A9 group.




Figure 7

Figure 7 S100A9 overexpression promoted macrophage polarization in ovalbumin-sensitized and challenged mice.

BALB/C mice are sensitized and challenged with ovalbumin (OVA). They were divided into groups receiving 3-bromopyruvate (3-BP), S100A9 plasmid intervention, or both. The resulting groups were OVA, OVA + 3-BP, OVA + OE-S100A9, and OVA + OE-S100A9 + 3-BP ($n=6$ per group). (A, B) Flow cytometry was used to detect polarization of macrophages in broncho-alveolar lavage fluid (BALF); compared to OVA- sensitized and challenged mice, the proportion of M1 (CD86+) and M2 (CD206+) macrophages was decreased in mice with OVA and 3-BP administration, while in OVA-sensitized and challenged mice with S100A9 overexpression, they were increased. (C) Immunohistochemistry was used to observe the expression levels of macrophage biomarkers. CD68 is a macrophage biomarker, IRF-5 is an M1 macrophage biomarker, and YM-1 is an M2 macrophage biomarker. (D) Statistic analysis of immunohistochemical image; CD68, IRF-5, and YM-1 positive cells were all decreased in OVA-sensitized and challenged mice with 3-BP administration, but they were significantly increased after S100A9 overexpression. (E-H) In the lung, the mRNA of IL-6, iNOS, Arg1, and IL-10 were detected by quantitative real-time PCR; IL-6, iNOS and Arg1 were decreased in OVA-sensitized and challenged mice with 3-BP intervention and increased in OVA-sensitized and challenged mice with S100A9 overexpression, while IL-10 has the opposite trend. (mean \pm standard deviation) $^{\#}p < 0.05$, $^{\#\#}p < 0.01$ compared to OVA group; $^{+}p < 0.05$, $^{++}p < 0.01$ compared to OVA + OE-S100A9 group.




Figure 8

Figure 8 S100A9 overexpression inhibited glycolysis in ovalbumin-sensitized mouse lung tissue.

Ovalbumin (OVA) sensitized BALB/C mice were divided into groups receiving 3-bromopyruvate (3-BP), S100A9 plasmid intervention, or both. The resulting groups were OVA, OVA + 3-BP, OVA + OE-S100A9, and OVA + OE-S100A9 + 3-BP. (A) Serum lactic acid concentration was measured by using a spectrophotometer ($n=6$). (B-D) Pyruvate dehydrogenase (PDH), lactate dehydrogenase (LDH) A and hexokinase (HK) 2 are key enzymes of glycolysis and mRNAs of them were decreased in mice post-OVA-challenged with 3-BP intervention, while they were increased in OVA-sensitized and challenged mice by S100A9 overexpression ($n=3$). Quantitative real-time PCR is used for mRNA measurement. (E-M) Western blot is used for measurement of LDHA, HK2, TLR4, MyD88, p-NF- κ B/NF- κ B, p-I κ B α /I κ B α , Gasdermin D-N, and cleaved-caspase-1/caspase-1 levels ($n=3$). Compared to OVA-sensitized and challenged mice, they were all decreased in OVA-sensitized mice by 3-BP intervention and increased in OVA-sensitized and challenged mice with S100A9 overexpression. In addition, 3-BP can antagonize the promotion of S100A9 overexpression on glycolysis. (mean \pm standard deviation) $^{\#}p < 0.05$, $^{\#\#}p < 0.01$ compared to OVA group; $^{++}p < 0.01$ compared to OVA + OE-S100A9 group.




Table 1(on next page)

Table 1 Primer sequences information

All primer sequences were viewed in Table 1

1 Tables**2 Table 1 Primer sequences information**

3	4	5	6	Gene	5'-Forward Primer-3'	5'-Reverse Primer-3'	Sequence accession number	Amplicon length (bp)
				Mouse S100A8	AAATCACCATGCCCTCTACAAG	CCCACTTTATCACCATCGCAA	NM_013650.2	165
				Mouse S100A9	ATACTCTAGGAAGGAAGGACACC	TCCATGATGTCATTATGAGGGC	NM_001281852.1	129
				Mouse iNOS	GGAGTGACGGCAAACATGACT	TCGATGCACAACGGGTGAAC	NM_001313922.1	127
				Mouse IL-6	TCTATACCACTTCACAAGTCGGA	GAATTGCCATTGCACAACTCTTT	NM_001314054.1	88
				Mouse Arg1	TGTCCCTAATGACAGCTCCTT	GCATCCACCCAAATGACACAT	NM_007482.3	204
				Mouse IL-10	CTTACTGACTGGCATGAGGATCA	GCAGCTCTAGGAGCATGTGG	NM_010548.2	101
				Mouse PDH	TGTGACCTTCATCGGCTAGAA	TGATCCGCCTTAGCTCCATC	NM_008810.3	119
				Mouse HK2	TGATCGCCTGCTTATTACCGG	AACCGCCTAGAAATCTCCAGA	NM_013820.4	112
				Mouse LDHA	CAAAGACTACTGTGTAATGCGA	TGGACTGTACTTGACAATGTTGG	NM_001136069.2	148
				Mouse GAPDH	CGAGACACGATGGTGAAGGT	TGCCGTGGGTGGAATCATAAC	NM_001411843.1	282
				Mouse IL-1 β	GAAATGCCACCTTTGACAGTG	TGGATGCTCTCATCAGGACAG	NM_008361.4	116
				Mouse Fizz1	CCAATCCAGCTAACTATCCCTCC	ACCCAGTAGCAGTCATCCCA	NM_020509.4	108
				Mouse β -actin	GGCTGTATTCCCTCCATCG	CCAGTTGGTAAACAATGCCATGT	NM_007393.5	154

Table 2(on next page)

Table 2 Effects of S100A8 and S100A9 knockdown on EACR in MH-S cells with OVA

Extracellular Acidification Rate (EACR) was used to observe glycolysis in MH-S cells.

1

2 **Table 2 Effects of S100A8 and S100A9 knockdown on EACR in MH-S cells with OVA**

Group	ECAR (mpH/min)							
	1min	9min	18min	27min	36min	45min	54min	63min
Control	65.68±4.11	44.62±2.08	36.41±3.2	54.32±4.03	75.77±5.58	50.75±4.6	53.05±2.95	41.28±4.11
OVA	80.33±7.74 **	65.67±5.58 **	51.54±4.62 **	76.06±4.31 **	91.35±4.69 **	70.73±6.52 **	74.28±7.37 **	50.17±5.46 *
OVA + sh-S100A8	75.53±5.39	55.12±4.29 #	40.99±4.51 ##	64.18±3.7 ##	85.03±6.06	61.09±4.89 #	64.38±5.22 #	35.16±3.33 ##
OVA + sh-S100A9	70.09±5.87	35.35±3.9 ##	43.15±3.66 #	59.86±6.2 ##	80.29±6.72 #	55.41±4.68 ##	57.01±3.96 ##	42.37±3.69 #
OVA + sh-S100A8 + LPS	86.75±6.45 ^	65.15±6.07 ^	55.28±4.12 ^	75.52±4.57 ^	96.47±6.2 ^	72.01±3.76 ^	75.4±5.72 ^	55.35±4.62 ^
OVA + sh-S100A9 + LPS	76.98±7.2	64.25±8.79 ++	52.76±5.52 ++	72.71±5.29 ++	87.55±5.98	73.78±4.3 ++	74.25±5.57 ++	50.84±4.29 +

3 **: $p<0.01$, compared to Control group;4 #: $p<0.05$, compared to OVA group;5 ##: $p<0.01$, compared to OVA group;6 ^: $p<0.05$, compared to OVA + sh-S100A8 group;7 ^^: $p<0.01$, compared to OVA + sh-S100A8 group;8 +: $p<0.05$, compared to OVA + sh-S100A8 group;9 ++: $p<0.01$, compared to OVA + sh-S100A8 group;

10

11